Integrating heterogeneous data to facilitate COVID-19 drug repurposing |
| |
Institution: | 1. ETS Ingenieros Informáticos, Universidad Politécnica de Madrid, 28660 Boadilla del Monte, Madrid, Spain;2. Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28660 Boadilla del Monte, Madrid, Spain;3. Ezeris Networks Global Services S.L., 28028 Madrid, Spain;4. Facultativo Especialista Área (FEA), Anestesiología y Reanimación, Hospital Sierrallana, Servicio Cántabro de Salud, 39300 Torrelavega, Cantabria, Spain |
| |
Abstract: | In the COVID-19 pandemic, drug repositioning has presented itself as an alternative to the time-consuming process of generating new drugs. This review describes a drug repurposing process that is based on a new data-driven approach: we put forward five information paths that associate COVID-19-related genes and COVID-19 symptoms with drugs that directly target these gene products, that target the symptoms or that treat diseases that are symptomatically or genetically similar to COVID-19. The intersection of the five information paths results in a list of 13 drugs that we suggest as potential candidates against COVID-19. In addition, we have found information in published studies and in clinical trials that support the therapeutic potential of the drugs in our final list. |
| |
Keywords: | COVID-19 SARS-COV-2 Drug repurposing Data-driven approaches |
本文献已被 ScienceDirect 等数据库收录! |
|